Search Results
Unleashing Potential of Early Initiation of SGLT2-i & DPP4-i in Diabetes Management
Paradigm shift in the management of T2DM with CV complications: Opportunities with DPP4-i & SGLT2-i
Dr Julie Lovshin - SGLT2i Cardiorenal mechanisms in diabetes and beyond - summary presentation
Jubbin Jacob :Addressing CaReMe Syndrome : Role of FDC of DPP4i and SGLT2i
Making Choices: DPP-4 Inhibitors , SGLT-2 Inhibitors Or Both - Prof. Leszek Czupryniak
DPP4i & SGLT2i: Perfect Partners
The Cardio - Renal and Metabolic Approach to Diabetes - Speaker - Dr JJ Mukherjee
Professor Alice Cheng - SGLT inhibitors - are there no therapeutic limits
Professor Mansoor Husain - GLP-1 analogues - have the limits been reached? - Full version
10 considerations to use DPP IV i for the clinician - Dr CR Anand Moses
Dr. Vijay Negalur - Legacy of Vildagliptin
0204 : Clinical Excellence In Cardio-Renal-Metabolic Care In T2DM : SGLT2i + DPP4i FDC
